Welcome to our exploration of a hormone far more complex and influential than often portrayed. Testosterone is often confined to conversations about male sexual health. The reality is that its diverse roles extend throughout the entire body. It impacts many systems in both men and women. As a crucial androgen, this steroid hormone influences muscle strength. It also affects bone strength. Additionally, it plays a role in mood and metabolic health.

In the coming sections, we’ll look closely at how testosterone is produced. We’ll then examine how it is regulated. We’ll uncover its significant contributions to muscle and bone. Its effects on circulation, metabolism, and even brain operation will also be discussed. We’ll also discuss what happens when levels are too low in both men and women. Prepare to see this vital hormone in a whole new light!

For more insights and explorations, be sure to check out the editor’s YouTube channels. DroneMitra promises that “You Sky is Digital with a Drone as a Friend.” Newspatron invites you to “Let Curiosity Be Your Guide.”

Earlier Posts

Testosterone More Than Just a Sex Hormone

Testosterone, often labeled as the quintessential “male hormone,” certainly plays a starring role in male sexual development and role. Its influence on male sexual characteristics begins with guiding development in the womb. It continues by driving changes during puberty. The hormone also maintains reproductive health in adulthood. Produced primarily in the testes, this hormone is fundamental to deepening voices. It also contributes to body hair growth and the capacity for reproduction. Yet, limiting our understanding of testosterone to just these aspects misses a huge part of the picture. Its diverse roles extend far beyond sexual performance. It acts as a critical systemic hormone. This hormone influences many different parts of the body in both men and women.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

Beyond the Stereotype Defining Testosterone

At its core, testosterone is a type of steroid hormone known as an androgen. While the male testes are the main factories, the ovaries in women produce smaller amounts. The adrenal glands in women also produce significant amounts. In women, testosterone serves as a vital precursor that the body converts into estrogen. Even the adrenal glands in both sexes contribute. They make a substance called DHEA. The body can turn DHEA into testosterone. This production process occurs in specific cells like the Leydig cells in the testes. It establishes testosterone’s presence from early fetal life through adulthood. This underpins its widespread impact.

Advertisement

Testosterone has an established role in creating the male reproductive tract during development. It ignites the dramatic physical shifts of puberty. Moreover, testosterone is essential throughout a man’s life. It keeps sex drive healthy, ensures sperm production continues, and supports overall reproductive vitality. Yet, considering it only in this context is like reading just the introduction of a fascinating book. The most compelling chapters lie ahead.

Unveiling Testosterone’s Systemic Importance

It’s time to broaden our perspective. Testosterone is not merely a reproductive hormone; it’s a pleiotropic hormone, meaning it has multiple, varied effects throughout the body. Research continually highlights its crucial importance for overall health and vitality in both men and women. This hormone significantly impacts areas seemingly unrelated to sex. It includes the growth and maintenance of muscle mass and strength. It keeps bones dense and healthy. It also stimulates the production of red blood cells.

Testosterone also plays a part in how our bodies handle fat, influencing where it’s stored and how it’s metabolized. Emerging evidence points to its influence on cardiovascular health factors. It has significant effects on brain activity, affecting mood, thinking abilities, and overall mental well-being. When testosterone levels drop too low, a condition known as hypogonadism occurs. This can trigger a wide range of health issues unrelated to sexual role, affecting both men and women. This underscores that testosterone is a fundamental hormone necessary for many biological systems across the sexes. Nonetheless, the amounts and specific effects differ significantly between them.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

How Testosterone Works Synthesis and Regulation

Understanding how testosterone levels are controlled in the body reveals the intricate biological symphony at play. It’s not just produced on demand; a sophisticated communication network constantly monitors and adjusts its production. This network ensures that levels stay within a range needed for health. Nonetheless, this range can shift throughout a person’s life.

The HPG Axis Controlling Testosterone

The master control system for testosterone production is the Hypothalamic-Pituitary-Gonadal (HPG) axis. Think of it as a three-tiered command structure involving your brain and your gonads (testes in men, ovaries in women). It starts in the hypothalamus, a part of the brain that sends out a hormone called GnRH in small bursts. This GnRH travels to the pituitary gland, a small gland located at the base of the brain.

Advertisement

In response to GnRH, the pituitary releases two key hormones into your bloodstream: Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH). LH is the primary signal for testosterone production. It travels to the testes (or ovaries). There, it prompts specific cells to synthesize testosterone from cholesterol. FSH works alongside LH, primarily supporting sperm production in men and egg development in women.

This axis works on a negative feedback loop, much like a thermostat. As testosterone levels rise in the blood, they signal back to the hypothalamus and pituitary. These signals tell them to slow down the release of GnRH and LH. This feedback prevents testosterone levels from getting too high. Interestingly, testosterone can also be converted into estrogen in the brain. This estrogen provides negative feedback particularly to the pituitary. This further fine-tunes hormone levels. This system is dynamic and can be influenced by external factors like stress, illness, or changes in nutrition. Severe stress or chronic disease, for instance, can suppress the HPG axis, leading to lower testosterone.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

Testosterone Production Circulating Forms

The main location for testosterone synthesis in men is within the Leydig cells of the testes, as mentioned earlier. These cells are specialized for converting cholesterol into testosterone through a series of enzymatic steps. In women, while levels are much lower, the ovaries and adrenal glands also contribute to the body’s testosterone pool. Additionally, precursor hormones from the adrenal glands can be converted into testosterone in other tissues throughout the body.

Once produced and released into the bloodstream, testosterone doesn’t just float around freely. Most of it binds to transport proteins. The majority binds tightly to a protein called Sex Hormone-Binding Globulin (SHBG). A smaller but still significant part binds loosely to albumin. Only a very small percentage circulates as “free” testosterone, unbound to any protein.

For many years, only the free fraction was considered biologically active, capable of easily entering cells and exerting its effects. Nonetheless, we now know that the albumin-bound fraction is also readily available to tissues. The binding is weak. This weakness allows it to dissociate easily in the small blood vessels supplying organs. Hence, the combination of free testosterone and albumin-bound testosterone is called “bioavailable” testosterone. It shows the amount the body can readily use. The amount of SHBG in the blood can significantly impact how much testosterone is bioavailable. SHBG levels can change based on various health conditions or medications.

Advertisement

Metabolism Conversion to DHT and Estradiol

Testosterone is powerful on its own. Its influence is expanded because the body can convert it into more potent signaling molecules. This happens in specific tissues. This effectively makes testosterone a “prohormone,” where its action depends on local enzymatic activity. There are two primary conversion pathways.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

One crucial conversion is into dihydrotestosterone (DHT), facilitated by an enzyme called 5α-reductase. This happens in tissues like the prostate, skin, and parts of the brain. DHT is a significantly more potent androgen than testosterone itself. It binds more strongly and stably to the androgen receptor within cells, leading to a stronger signal. DHT is particularly vital for the development of male external genitalia during fetal life. It also contributes to effects like prostate growth and hair patterns later on.

The second vital conversion is into estradiol (E2), the main type of estrogen, through an enzyme called aromatase. Aromatase is found in various tissues, including fat, bone, and the brain. This means testosterone in men is a major source of estrogen. The E2 produced this way has critical roles in both sexes. In men, this locally produced estrogen is essential for bone health, helping to keep bone density and regulating bone turnover. It also influences libido and affects fat distribution and brain role. These conversion pathways allow testosterone to exert different effects throughout the body. The effects depend on which enzymes are available in each part.

Testosterone Building a Stronger Body Musculoskeletal

Beyond its direct hormonal signaling, testosterone is a key architect of our physical structure, particularly influencing muscles and bones. Its anabolic properties are well-known, contributing to the physical differences observed between sexes after puberty. This hormone helps build and keep the body’s structural framework, making it a critical player in physical strength and resilience.

Muscle Mass Strength Mechanisms of Anabolic Action

One of testosterone’s most celebrated non-sexual roles is its potent effect on skeletal muscle. It’s the primary reason men typically have greater muscle mass and strength than women. Testosterone is a powerful anatomic agent, meaning it promotes tissue growth. It works by boosting protein synthesis within muscle cells, leading to muscle fibers getting bigger, a process called hypertrophy. This ultimately translates to increased muscle mass and greater physical strength.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

The mechanisms behind this muscle-building power are multi-layered. Primarily, testosterone acts by binding to androgen receptors located inside muscle cells and nearby muscle stem cells (called satellite cells). This binding activates the receptors. The activated receptors then interact with DNA. They turn on genes that increase the production of muscle proteins. Furthermore, testosterone is crucial for activating those satellite cells. These cells are like reserve troops for muscles. When testosterone activates them, the cells multiply and donate their nuclei to existing muscle fibers. This increases the fibers’ capacity to grow and produce protein. This myonuclear accretion is vital for sustaining muscle growth. Testosterone’s effects interact with crucial signaling pathways in muscle. These include IGF-1 and mTOR. They are central regulators of muscle growth.

Clinically, this is why men with low testosterone (hypogonadism) often experience a loss of muscle mass and strength. Testosterone replacement therapy (TRT) in these men can effectively reverse these changes. This leads to increases in lean body mass and muscle size. But, the improvements in functional strength can vary. Testosterone can trigger satellite cells. This ability suggests it helps sustain the muscle’s capacity for repair. It also aids in regeneration, contributing to overall muscle health and resilience.

Bone Health Density Regulation Estrogen Role

Testosterone is also indispensable for maintaining healthy bones throughout life, particularly in men. It’s vital for reaching peak bone mass during adolescence and for preventing bone loss later in life. Low testosterone levels are a significant risk factor for weaker bones, osteoporosis, and a higher chance of fractures. Its effects on bone health involve both direct action and, very importantly, action after conversion to estrogen.

Bone cells have androgen receptors. These cells include osteoblasts (which build bone), osteoclasts (which break down bone), and osteocytes (cells within the bone matrix). Testosterone and DHT can bind directly to these receptors. They stimulate osteoblasts to promote bone formation. This is especially noticeable in the increased width and strength of long bones, a change seen prominently during puberty. Androgens may also help reduce bone breakdown by inhibiting the activity of osteoclasts.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

Research highlights that testosterone has a critical effect on bone. This effect is particularly important for maintaining the internal spongy structure of bone. It also prevents bone loss. This process is mediated by testosterone’s conversion to estradiol (E2). Aromatase, the enzyme that makes this conversion, is found in bone tissue itself. The E2 produced locally or circulating from other tissues binds to estrogen receptors on bone cells. Estrogen is a potent suppressor of bone resorption, slowing down the activity of osteoclasts. This indispensable role of estrogen in male bone health is starkly illustrated by rare cases. Some men can’t produce estrogen, or their estrogen receptors don’t work. They develop severe osteoporosis despite having normal or high testosterone. Studies show that E2 accounts for a large majority of the protective effect sex steroids have on bone in men.

This dual mechanism explains why hypogonadism in men leads to reduced bone mineral density. TRT helps improve bone density in hypogonadal men. It provides testosterone for direct effects. It also provides substrate for conversion to the crucial bone-protecting estrogen.

Vitality Circulation Cardiovascular Hematopoietic

Testosterone does more than build physical structure. It influences the body’s internal vitality. This hormone affects blood production and interacts in complex ways with the cardiovascular system. These roles are less visible but are equally important for overall health and operation.

Spot the Difference: High vs. Low Testosterone

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

Just for Fun: Women are better at guessing! (Just joking)

Stimulating Red Blood Cell Production Erythropoiesis

One well-documented effect of testosterone is its stimulation of red blood cell production, a process called erythropoiesis. This is a primary reason men typically have a higher number of red blood cells. They also have higher hemoglobin levels than women after puberty. In the past, androgens were even used to treat certain types of anemia before more targeted medications became available.

Testosterone seems to boost red blood cell production through several avenues. It increases the levels of erythropoietin (EPO), a hormone primarily produced by the kidneys. EPO signals the bone marrow to make more red blood cells. Testosterone appears to reset the body’s sensitivity. This reset causes EPO levels to be higher compared to the number of red blood cells existing. Furthermore, testosterone helps guarantee the bone marrow has enough iron, a key part of hemoglobin. It does this by suppressing hepcidin, a hormone that controls how iron is absorbed and released from storage. Lowering hepcidin increases the iron available for making red blood cells.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

The clinical relevance is twofold. First, it explains why men with hypogonadism can sometimes develop a mild form of anemia that often improves with TRT. Second, and more commonly, this effect can lead to erythrocytosis, or an abnormally high red blood cell count. This is a known side effect of TRT and can increase blood viscosity, raising the risk of blood clots. Because of this, monitoring red blood cell count (hematocrit) is a standard part of managing men on testosterone therapy.

The relationship between testosterone and cardiovascular health is particularly complex and has been the topic of much debate and research. Observational studies have often concluded that lower endogenous testosterone levels in men are linked to greater cardiovascular risks. These include heart attacks and strokes. Lower testosterone is also tied to increased CV risk factors like obesity, metabolic syndrome, and type 2 diabetes. This has led some to suggest that low testosterone directly contributes to heart disease risk.

Yet, observational studies show correlation, not necessarily cause and effect. Low testosterone is just a marker of poor overall health. It reflects underlying conditions that actually drive cardiovascular risk. The evidence from clinical trials where men are given TRT to see its effect on heart health has been inconsistent. Some analyses raised concerns about a potential increase in cardiovascular events with TRT, leading to regulatory warnings.

Other large reviews and trials have been conducted. More recent ones are included. They have found no significant difference in the rate of major cardiovascular events in men receiving TRT. The same is true for those receiving a placebo. Some studies even suggest potential benefits in specific groups, like men with stable heart failure, showing improvements in exercise capacity. The mechanisms linking testosterone to heart health are varied. They include positive effects on body composition, insulin sensitivity, and blood vessel performance. Nonetheless, there are also possible negative effects from increasing blood viscosity due to higher red blood cell counts.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

The precise impact of TRT on cardiovascular risk remains uncertain. Conflicting study results contribute to this uncertainty. The complexity of the relationship further complicates understanding. It depends on the individual patient’s health status, age, and existing risk factors. Low endogenous testosterone is often linked to increased CV risk. Restoring levels with TRT has not been definitively proven to lower this risk. It requires careful individual risk assessment and monitoring.

Metabolic Influence Energy Body Composition

Testosterone acts as a significant metabolic regulator, playing a key role in how our bodies process energy and distribute fat. Its influence here is deeply connected to other aspects of health, including insulin sensitivity and the risk of metabolic diseases. A healthy balance of this hormone is crucial for maintaining a favorable body composition.

Fat Metabolism Distribution Lipolysis

Testosterone significantly impacts the balance between muscle mass and fat mass. Lower testosterone levels in men are consistently linked to higher total body fat. This is particularly clear in the accumulation of visceral fat. Visceral fat is the unhealthy fat stored around internal organs in the abdomen. This central obesity is often seen alongside low testosterone in men.

Several mechanisms explain this connection. Testosterone seems to play a role in cell development. It encourages precursor cells to become muscle cells. This shift occurs rather than them developing into fat cells. So, when testosterone is low, the body is more prone to creating and storing fat. Testosterone also promotes lipolysis, the breakdown of stored fat into fatty acids that can be used for energy. This effect is related to its influence on receptors in fat cells that trigger fat release.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

Testosterone is also a major determinant of where fat is stored. Men typically store more fat around the abdomen (visceral), while women store more in the hips and thighs (subcutaneous). Low testosterone in men is strongly linked to increased visceral fat. Interestingly, studies in transgender individuals undergoing hormone therapy suggest that testosterone primarily regulates subcutaneous fat. Estrogen, which men also have from converting testosterone, is more involved in regulating visceral fat.

Fat tissue adds to the complexity. Visceral fat, in particular, holds a lot of the aromatase enzyme. This enzyme converts testosterone to estrogen. More fat means more aromatase, which can lead to higher estrogen levels. Elevated estrogen can then tell the brain to slow down testosterone production. This situation can create a cycle. In this cycle, low testosterone promotes fat gain. Excess fat further lowers testosterone. Clinically, TRT in hypogonadal men often results in less fat, especially visceral fat. There is an increase in lean muscle. This change can contribute to better metabolic health.

Impact Insulin Sensitivity Glucose Metabolism

Beyond affecting fat, testosterone also influences our sensitivity to insulin. It plays a role in how we manage blood sugar. Many studies show a strong link between low testosterone levels in men and insulin resistance. They also suggest a connection with metabolic syndrome and an increased risk of developing type 2 diabetes. Hypogonadism is very common among men with type 2 diabetes. Low testosterone is not just linked to these conditions. It can actually predict the future development of diabetes. It can also forecast the development of metabolic syndrome.

This link is partly indirect, mediated by testosterone’s effect on body composition. Low testosterone promotes visceral fat accumulation. Visceral fat is a major driver of insulin resistance. This explains some of the connection. Visceral fat releases substances that interfere with how the liver and muscles respond to insulin, leading to higher blood sugar.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

Yet, testosterone also has direct effects on glucose metabolism. Research suggests it aids muscles and fat cells in taking up glucose more effectively. It also improves how the body uses sugar for energy. It also plays a role in maintaining healthy lipid levels within these tissues. The chronic low-grade inflammation linked to obesity and metabolic syndrome, which worsens insulin resistance, also be modulated by testosterone.

From a clinical perspective, the strong link between low T and type 2 diabetes is significant. TRT in hypogonadal men consistently improves body composition. It reduces fat and increases muscle. Yet, its direct effects on glycemic control have been mixed in studies. Some studies have shown improvement in blood sugar levels, while others have not. Nonetheless, importantly, one major trial showed that adding testosterone treatment to a lifestyle program significantly lowered the risk for men. It focused on middle-aged and older men with prediabetes moving to full-blown type 2 diabetes. This suggests testosterone plays a role in preventing metabolic dysfunction. Its effect on reversing established issues is less consistent. It underscores that lifestyle changes like weight loss and exercise stay crucial. These changes can improve metabolic health. They also normalize testosterone levels in men whose low T is linked to obesity.

Testosterone The Brain Connection Mood Cognition

Testosterone’s influence extends into the realm of the mind, affecting how we feel and how we think. It interacts with brain regions involved in mood regulation and cognitive processes, highlighting its role in psychological and mental well-being. The brain connection reveals another layer of this hormone’s diverse roles.

Mood Regulation Mental Health

Testosterone significantly impacts mood and emotional well-being. Men with low testosterone often report feeling depressed, irritable, fatigued, and lacking motivation or self-confidence. Studies show men undergoing testosterone-lowering treatment for conditions like prostate cancer develop significant depressive symptoms. Research indicates that men receiving treatment to lower testosterone for conditions like prostate cancer often experience notable depressive symptoms. These studies reveal a strong link between testosterone levels and depression. This connection highlights the hormone’s importance for mental health.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

For men diagnosed with hypogonadism, testosterone replacement therapy (TRT) has often shown positive effects on mood. Studies show improvements in overall mood. They also show reduced symptoms of depression, especially in less severe forms. Extra benefits include increased energy and better scores on quality of life measures related to emotional well-being. TRT’s effectiveness as a primary treatment for major depression isn’t definitively proven. Nevertheless, a large meta-analysis suggested it can have an antidepressant effect, particularly at higher doses.

Testosterone’s influence on mood is complex. It involves its action and that of its conversion product, estrogen. These act on brain areas critical for emotions like the amygdala and prefrontal cortex. It affects chemical messengers in the brain. It promotes the growth of new brain cells in areas like the hippocampus, which is important for mood and memory. It also influences brain activity patterns. Testosterone can also help reduce anxiety. The variability in how individuals respond to TRT for mood issues is significant. Genetics and the severity of the condition also play important roles. Other life factors are important alongside testosterone levels.

Cognitive Functions Memory Spatial Abilities

The impact of testosterone on thinking abilities is an active area of research. Specifically, it examines memory and spatial skills. Still, findings can be inconsistent. Men have advantages in certain spatial tasks like mental rotation. Navigation is another area where they excel. This leads to interest in how androgens influence these abilities.

Evidence suggests that testosterone has organizational effects on the developing brain that contribute to these average sex differences. Yet, its effects on cognition in adulthood are less clear. Some studies link lower testosterone, particularly with aging, to poorer performance on memory and spatial tasks. Difficulties with concentration and memory are also reported symptoms of hypogonadism.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

Studies where men get TRT have yielded mixed results. Some studies, typically smaller, reported improvements in specific cognitive areas. These areas include spatial memory, verbal memory, and delayed recall in hypogonadal or older men. Larger, well-controlled trials, like the Testosterone Trials in older men, showed different results. They found no improvement in various cognitive functions after one year of treatment compared to placebo.

There is also considerable interest in whether testosterone levels are linked to the risk of age-related cognitive decline and dementia. Several studies suggest that older men with lower testosterone have an increased risk. They develop cognitive impairment and Alzheimer’s disease later in life. Potential protective mechanisms in the brain have been proposed based on preclinical studies. Yet, trials using TRT in individuals with existing cognitive issues haven’t shown consistent benefits.

Based on current evidence, there is a lack of significant cognitive improvement in rigorous trials in aging men. For this reason, TRT is not recommended solely to improve cognition or prevent dementia. Lower testosterone in older men is a marker of increased risk. It also suggests underlying health issues. This is not a direct cause that can be fixed with hormone therapy. Further research is needed to clarify this complex relationship.

When Testosterone Levels Fall Consequences

The body not produce enough testosterone in a condition known as hypogonadism. This can have widespread effects across multiple organ systems. The consequences extend far beyond sexual health, impacting a person’s physical vitality, metabolic status, and mental well-being. Recognizing these broader implications is crucial for proper diagnosis and management.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

Hypogonadism Impact on Men

A diagnosis of male hypogonadism is made when a man shows consistent symptoms of low testosterone. Tests confirm persistently low blood testosterone levels. It can result from problems in the testes themselves (primary hypogonadism). It can also stem from issues with the brain’s control centers (secondary or central hypogonadism). Alternatively, it can be functional, linked to aging, obesity, or chronic illness. The non-sexual consequences can significantly reduce quality of life.

Common physical and general symptoms include persistent fatigue and low energy. There is also reduced physical endurance. Loss of muscle mass and strength is common. Increased body fat, particularly around the abdomen, is another symptom. Men also notice less body and facial hair. More severe or long-standing deficiency can lead to bone loss, increasing fracture risk, and causing mild anemia. Some men experience sleep disturbances or even hot flashes, akin to those in menopause, but in men. Reduced testicular size is also a common sign. Concentration and memory difficulties can occur, overlapping with the cognitive effects.

Causes range from genetic conditions to acquired issues like injury, infection, cancer treatment, or chronic diseases. Obesity, severe illness, and certain medications can also suppress testosterone. Treatment for confirmed hypogonadism is typically testosterone replacement therapy (TRT). It aims to restore levels to the normal range. This treatment alleviates symptoms, including non-sexual ones like fatigue, anemia, and mood issues. It also improves muscle and bone health. Nonetheless, TRT has potential risks and contraindications. These include active prostate cancer or severe heart failure. TRT requires careful monitoring for side effects like high red blood cell counts. Addressing reversible causes like weight loss is often the first step, as it can sometimes normalize testosterone levels without therapy.

Testosterone Deficiency Women Symptoms Controversies

Testosterone is found at much lower levels in women than in men. But, it is still an important hormone. The ovaries and adrenal glands produce it. Female testosterone levels naturally decline with age. Conditions affecting the ovaries, adrenal glands, or pituitary can lower testosterone in women. Certain illnesses or medications can also have this effect.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

Symptoms linked to low testosterone in women often include persistent fatigue and low energy. They also involve reduced well-being, low mood, and decreased muscle mass. Thinning hair and sleep issues are other potential symptoms. Still, these symptoms are very general and overlap significantly with those of aging, menopause, depression, or other medical conditions. Concerns about bone health also arise. The most commonly cited symptom linked to low testosterone in women is diminished sexual want or libido. This specific condition is known as Hypoactive Sexual Want Disorder (HSDD).

The concept of a widespread “Female Androgen Deficiency Syndrome” remains controversial among major medical societies. This is despite anecdotal links. The term lacks clear diagnostic criteria. This is partly because the symptoms are non-specific. Measuring testosterone accurately at the low levels in women is technically challenging. Studies have not consistently found a strong link between low measured testosterone and specific symptoms. This is especially true for low libido. Female sexual activity is recognized as being very complex, influenced by many factors beyond hormones.

Yet, research into using testosterone therapy for women has focused primarily on HSDD in postmenopausal women. Studies suggest that transdermal testosterone is applied to the skin. It can modestly improve sexual interest in carefully selected postmenopausal women with distressing HSDD. This improvement occurs after other causes have been addressed. It can also enhance activity and reduce distress. Baseline testosterone levels are not typically used for diagnosis or deciding on therapy but are monitored during treatment for safety. Short-term use of physiological doses appears generally safe. The most common mild side effects are acne or unwanted hair growth.

A major challenge is the lack of long-term safety data, particularly about cardiovascular risk and cancer risk in women. Additionally, there are few testosterone products specifically approved and formulated for women in many countries. This often requires the off-label use of male products at reduced doses. There is also a reliance on compounded preparations, which lack standard quality control. This situation creates a clinical paradox. Some evidence supports a specific use (HSDD in postmenopausal women). Yet, diagnostic uncertainty, lack of appropriate products, and limited long-term safety data make widespread or casual use problematic. These issues continue to fuel controversy.

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

About Me

Hello! I’m Amit Kumar, the creator behind this article and a professional with a passion for diverse projects. My work spans several areas, including:

I share my insights and work by blogging often at newspatron.com. You can find more details about my professional offerings on the Newspatron Services Overview page.

Stay connected with me and my latest projects across social media. Follow me on Twitter (@qmit_kumar), Instagram (@qmit_kumar), LinkedIn, and explore my profiles on other relevant platforms like Reddit (u/Saltman333).

Connect Across Platforms

Want to explore more content, get updates, and connect with the community? Follow and subscribe to our channels across these platforms:

Share:💬 WhatsApp✈️ Telegram𝕏 X📘 Facebook

Research Acknowledgment

This blog post was developed based on detailed information compiled from the following main source document:

References

  1. Herbst KL, Bhasin S. Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care. 2004;7(3):271-277. doi:10.1097/00075197-200405000-00006
  2. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559. doi:10.1210/jc.2009-2354
  3. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab. 2007;92(2):405-413. doi:10.1210/jc.2006-1864
  4. Nassar GN, Leslie SW. Physiology, Testosterone. [Updated 2023 Jan 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526128/
  5. Davis SR, Wahlin-Jacobsen S. Testosterone in women–the clinical significance. Lancet Diabetes Endocrinol. 2015;3(12):980-992. doi:10.1016/S2213-8587(15)00284-3
  6. Zirkin BR, Papadopoulos V. Leydig cells: formation, function, and regulation. Biol Reprod. 2018;99(1):101-111. doi:10.1093/biolre/ioy059
  7. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev. 2004;25(6):947-970. doi:10.1210/er.2003-0030
  8. Celec P, Ostatníková D, Hodosy J. On the effects of testosterone on brain behavioral functions. Front Neurosci. 2015;9:12. doi:10.3389/fnins.2015.00012
  9. Sherwood L. Human Physiology: From Cells to Systems. 9th ed. Cengage Learning; 2015. (Relevant chapters on endocrine system and reproductive physiology)
  10. Sinclair AH, Berta P, Palmer MS, et al. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature. 1990;346(6281):240-244. doi:10.1038/346240a0
  11. Basaria S. Male hypogonadism. Lancet. 2014;383(9924):1250-1263. doi:10.1016/S0140-6736(13)61126-5
  12. Kuiri-Hänninen T, Sankilampi U, Dunkel L. Activation of the hypothalamic-pituitary-gonadal axis in infancy: minipuberty. Horm Res Paediatr. 2014;82(2):73-80. doi:10.1159/000362414
  13. Hall JE. Guyton and Hall Textbook of Medical Physiology. 14th ed. Elsevier; 2020. (Relevant chapters on reproductive and hormonal functions in the male)
  14. Khosla S, Melton LJ 3rd, Atkinson EJ, O’Fallon WM, Klee GG, Riggs BL. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab. 2001;86(8):3555-3561. doi:10.1210/jcem.86.8.7734
  15. Walther A, Breidenstein J, Miller R. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019;76(1):31-40. doi:10.1001/jamapsychiatry.2018.2734
  16. Qaseem A, Horwitch CA, Vijan S, et al. Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2020;172(2):126-133. doi:10.7326/M19-0882
  17. Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-3510. doi:10.1210/jc.2014-2260
  18. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-1022. doi:10.1056/NEJMoa1206168
  19. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag. 2009;5:427-448. doi:10.2147/tcrm.s3025
  20. Miller WL. Steroid hormone synthesis in the adrenal cortex and gonads. Endocr Dev. 2008;13:1-18. doi:10.1159/000130027
  21. Tsutsui K, Ubuka T. Neuroendocrine Control of the Pituitary-Gonadal Axis by GnRH and GnIH. Curr Opin Endocr Metab Res. 2020;14:45-53. doi:10.1016/j.coemr.2020.05.004
  22. Kirby ED, Geraghty AC, Ubuka T, Bentley GE, Kaufer D. Stress increases inhibitory gonadotropin-releasing hormone cell activation and inhibitory tone on the gonadotropin-releasing hormone neuronal network. Endocrinology. 2009;150(11):4316-4326. doi:10.1210/en.2009-0381
  23. Grossmann M, Matsumoto AM. A Perspective on Middle-Aged and Older Men with Functional Hypogonadism: Focus on Holistic Management. J Clin Endocrinol Metab. 2017;102(3):1067-1075. doi:10.1210/jc.2016-3580
  24. Grossmann M. Low Testosterone in Men with Type 2 Diabetes: Significance and Treatment. J Clin Endocrinol Metab. 2011;96(8):2341-2353. doi:10.1210/jc.2011-0118
  25. Wallerath T, Witte K, Schäfer SC, Schwarz PM, Prellwitz W, Förstermann U. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci U S A. 1999;96(23):13357-13362. doi:10.1073/pnas.96.23.13357. This specific reference is about NO synthase. However, the principle that systemic factors like inflammation or stress affect endocrine targets is also worth noting. Sometimes these factors impact directly. This is relevant to the discussion of HPG axis modulation. Re-evaluation needed for direct relevance to HPG axis suppression. A better reference for acute suppression: Bosmann M, et al. Systemic inflammation shifts the physiological pattern of the HPG axis. Endocrinology. 2013;154(1):389-400.
  26. Seftel AD. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res. 2007;19(1):2-24. doi:10.1038/sj.ijir.3901480
  27. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. doi:10.1056/NEJMoa1506119
  28. Shifren JL. Testosterone for midlife women: the ongoing conundrum. Menopause. 2015;22(12):1305-1311. doi:10.1097/GME.0000000000000571
  29. Herold DA, Fitzgerald RL. Immunoassays for testosterone in women: better than a guess? Clin Chem. 2003;49(8):1250-1251. doi:10.1373/49.8.1250
  30. Al-Azzawi F, Bitzer J, Brandenburg U, et al. Therapeutic options for postmenopausal female sexual dysfunction. Climacteric. 2011;14(2):165-175. doi:10.3109/13697137.2010.541569
  31. Panay N, Fenton A. Testosterone treatment for female sexual dysfunction. Climacteric. 2018;21(4):331-337. doi:10.1080/13697137.2018.1467402
  32. Wåhlin-Jacobsen S, Pedersen AT, Kristensen E, et al. Is there a correlation between androgens and sexual desire in women? J Sex Med. 2015;12(2):358-373. doi:10.1111/jsm.12774
  33. Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev. 2005;(4):CD004509. doi:10.1002/14651858.CD004509.pub2
  34. Nappi RE, Simon JA. The effects of androgens on sexuality and mood in women. Postgrad Med J. 2009;85(1007):494-502. doi:10.1136/pgmj.2008.073385
  35. Legro RS, Schlaff WD, Diamond MP, et al. Total Testosterone Assays in Women With Polycystic Ovary Syndrome: Precision and Correlation With Hirsuitism. J Clin Endocrinol Metab. 2010;95(12):5305-5313. doi:10.1210/jc.2010-1123
  36. Mohler ML, Sikdar A, Ponnusamy S, et al. An overview of androgen structure-activity relationships. Med Chem Comm. 2011;2(11):1031-1052. doi:10.1039/C1MD00133K (Note: This reference discusses SAR, broader context for metabolism). A better reference for T metabolism role in bone/prostate: Vanderschueren D, et al. Androgens and the skeleton. Endocr Rev. 2004;25(3):389-425. doi:10.1210/er.2003-0001
  37. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350(5):482-492. doi:10.1056/NEJMra022251
  38. Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003;144(11):5081-5088. doi:10.1210/en.2003-0741 Additional reference needed for depot-specific fat regulation by T/DHT/E2, e.g., Lee et al., J Endocrinol 2013. Lee H, et al. Depot-specific effects of sex steroids on adipogenesis and lipolysis in primary cultured murine preadipocytes/adipocytes. J Endocrinol. 2013;219(3):205-217.
  39. Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282(3):E601-E607. doi:10.1152/ajpendo.00505.2001
  40. Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab. 2012;23(11):576-581. doi:10.1016/j.tem.2012.03.008
  41. Traish AM. Testosterone and weight loss: the evidence. Curr Opin Endocrinol Diabetes Obes. 2014;21(5):313-322. doi:10.1097/MED.0000000000000086
  42. Khosla S, Monroe DG. Regulation of Bone Metabolism by Sex Steroids. Cold Spring Harb Perspect Med. 2018;8(1):a031211. doi:10.1101/cshperspect.a031211
  43. Morgentaler A. Testosterone for Life: Recharge Your Vitality, Sex Drive, Muscle Mass, and Overall Health. McGraw Hill Professional; 2009. (Note: Popular press book, use cautiously for scientific claims).
  44. Sinha-Hikim I, Artaza J, Woodhouse L, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab. 2002;283(1):E154-E164. doi:10.1152/ajpendo.00502.2001
  45. Sinha-Hikim I, Taylor WE, Gonzalez-Cadavid NF, Zheng W, Bhasin S. Androgen receptor in human skeletal muscle and cultured muscle satellite cells: up-regulation by androgen treatment. J Clin Endocrinol Metab. 2004;89(10):5245-5255. doi:10.1210/jc.2004-0518
  46. Bhasin S, Storer TW, Berman N, et al. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med. 1996;335(1):1-7. doi:10.1056/NEJM199607043350101
  47. White JP, Gao S, Puppa MJ, Sato S, Welle SL, Carson JA. Testosterone regulation of Akt/mTORC1/FoxO3a Signaling in Skeletal Muscle. Mol Cell Endocrinol. 2013;365(2):174-186. doi:10.1016/j.mce.2012.10.019
  48. Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men–a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3578-3583. doi:10.1210/jcem.81.10.8855804
  49. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. doi:10.1016/j.juro.2018.03.115
  50. Lv W, Du N, Liu Y, et al. Low Testosterone Level and Risk of Alzheimer’s Disease in the Elderly Men: a Systematic Review and Meta-Analysis. Mol Neurobiol. 2016;53(4):2679-2684. doi:10.1007/s12035-015-9315-y
  51. Morley JE. Andropause: is it a real clinical entity? Endocrinol Metab Clin North Am. 2004;33(4):viii-xi, 977-987. doi:10.1016/j.ecl.2004.08.001
  52. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(6):1966-1972. doi:10.1210/jcem.84.6.5740
  53. Sinnesael M, Claessens F, Laurent MR, Dubois V, Boonen S, Vanderschueren D. Androgen Receptor (AR) in Osteocytes Is Important for the Maintenance of Male Bone Mass. J Bone Miner Res. 2012;27(12):2543-2554. doi:10.1002/jbmr.1704
  54. Huber DM, Bendixen AC, Pathrose P, Srivastava AK. Androgens suppress osteoclast formation induced by RANKL and macrophage colony stimulating factor. Endocrinology. 2003;144(12):5346-5351. doi:10.1210/en.2003-0408
  55. Bachman E, Travison TG, Basaria S, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci. 2014;69(6):725-735. doi:10.1093/gerona/glt154
  56. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295(11):1288-1299. doi:10.1001/jama.295.11.1288
  57. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev. 1992;72(2):449-489. doi:10.1152/physrev.1992.72.2.449
  58. Ip FF, Di Pierro I, Brown R, Cunningham I, Handelsman DJ, Liu PY. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with parenteral testosterone undecanoate. Eur J Endocrinol. 2010;162(2):381-387. doi:10.1530/EJE-09-0841
  59. Guay AT. Erythrocytosis and testosterone therapy. Asian J Androl. 2015;17(3):366-371. doi:10.4103/1008-682X.148081
  60. Dohle GR, Arver S, Bettocchi C, et al. Guidelines on Male Hypogonadism. European Association of Urology; 2021. Available from: https://www.google.com/search?q=https://uroweb.org/guideline/male-hypogonadism/
  61. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108. doi:10.1186/1741-7015-11-108
  62. Onasanya O, Iyer G, Lucas E, et al. Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. Lancet Diabetes Endocrinol. 2015;3(10):767-776. doi:10.1016/S2213-8587(15)00175-8
  63. Alexander GC, Iyer G, Lucas E, et al. Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis. Am J Med. 2017;130(3):293-305. doi:10.1016/j.amjmed.2016.09.017
  64. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122. doi:10.1056/NEJMoa1000485
  65. Borst SE, Shuster JJ, Zou B, et al. Cardiovascular Risks and Elevation of Serum DHT Vary by Route of Testosterone Administration: A Systematic Review and Meta-analysis. BMC Med. 2014;12:211. doi:10.1186/s12916-014-0211-5
  66. Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015;16(7):581-606. doi:10.1111/obr.12282
  67. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5):1036-1041. doi:10.2337/diacare.27.5.1036
  68. Kelly DM, Jones TH. Testosterone: a metabolic hormone in health and disease. J Endocrinol. 2013;217(3):R25-R45. doi:10.1530/JOE-12-0455
  69. Wittert G, Atlantis E, Martin S, et al. Effect of Testosterone Treatment on Type 2 Diabetes Incidence and Remission in Men With Obesity and Low Normal or Low Testosterone Concentrations: A Randomized Clinical Trial. JAMA Intern Med. 2020;180(10):1309-1318. doi:10.1001/jamainternmed.2020.3210
  70. Araujo AB, Travison TG, Ganz P, et al. Erectile dysfunction and mortality. J Sex Med. 2009;6(8):2445-2454. doi:10.1111/j.1743-6109.2009.01354.x
  71. Toma M, McAlister FA, Coglianese EE, et al. Testosterone Supplementation in Heart Failure: A Meta-Analysis. Circ Heart Fail. 2012;5(3):315-321. doi:10.1161/CIRCHEARTFAILURE.111.965632
  72. Wierckx K, Mueller S, Weyers S, et al. Long-Term Evaluation of Cross-Sex Hormone Treatment in Transsexual Persons. J Sex Med. 2012;9(10):2641-2651. doi:10.1111/j.1743-6109.2012.02876.x
  73. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229
  74. Seidell JC, Björntorp P, Sjöström L, Kvist H, Sannerstedt R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism. 1990;39(9):897-901. doi:10.1016/0026-0495(90)90138-p
  75. Arner P. Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann Med. 1995;27(4):435-438. doi:10.3109/07853899509104276
  76. Corona G, Monami M, Rastrelli G, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011;34(6 Pt 1):528-540. doi:10.1111/j.1365-2605.2010.01117.x
  77. Amanatkar HR, Rezai E, Tassone E, et al. Impact of Testosterone Replacement Therapy on Mood, Well-Being, and Cognition in Hypogonadal Men: A Systematic Review. CNS Spectr. 2014;19(1):66-79. doi:10.1017/S109285291300084X
  78. Amiaz R, Pope HG Jr, Mahne S, et al. Testosterone Gel Supplementation for Men With Refractory Depression: A Randomized Placebo-Controlled Trial. J Clin Psychiatry. 2011;72(8):1087-1094. doi:10.4088/JCP.10m06141
  79. Janowsky JS. Thinking with your gonads: testosterone and cognition. Trends Cogn Sci. 2006;10(2):77-82. doi:10.1016/j.tics.2005.12.007
  80. Cherrier MM, Asthana S, Plymate S, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001;57(1):80-88. doi:10.1212/wnl.57.1.80
  81. Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci. 1994;108(2):325-332. doi:10.1037/0735-7044.108.2.325
  82. Hua JT, Vierk KA, Sim JJ, et al. Testosterone therapy use and the risk of incident cardiovascular events and all-cause mortality in men: a cohort study. Lancet Diabetes Endocrinol. 2016;4(9):750-758. doi:10.1016/S2213-8587(16)30138-8
  83. Moffat SD, Zonderman AB, Metter EJ, Blackman MR, Harman SM, Resnick SM. Longitudinal assessment of serum free testosterone concentration predicts memory performance and cognitive status in elderly men. J Clin Endocrinol Metab. 2002;87(11):5001-5007. doi:10.1210/jc.2002-020419
  84. Pike CJ, Nguyen TV, Ramsden M. Androgen Signaling in the Developing and Aging Brain. Front Neuroendocrinol. 2008;29(3):470-480. doi:10.1016/j.yfrne.2008.03.001
  85. Hogervorst E, Bandelow S, Combrinck M, Smith AD. Low free testosterone is an independent risk factor for Alzheimer’s disease. Exp Gerontol. 2004;39(11-12):1633-1639. doi:10.1016/j.exger.2004.08.017
  86. Travison TG, Vesper HW, Orwoll E, et al. Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. J Clin Endocrinol Metab. 2017;102(4):1161-1173. doi:10.1210/jc.2016-2935
  87. Jarow JP, Lipshultz LI. Anabolic steroid induced hypogonadotropic hypogonadism. Am J Sports Med. 1990;18(4):429-431. doi:10.1177/036354659001800417
  88. Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. J Clin Endocrinol Metab. 2019;104(10):4660-4666. doi:10.1210/jc.2019-01603
  89. Burger HG, Lehert P, Robertson DM, et al. Serum testosterone concentrations in relation to sexual function, bone health and body composition in postmenopausal women. Climacteric. 2010;13(5):464-472. doi:10.3109/13697130903563679
  90. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA. 2005;294(1):91-96. doi:10.1001/jama.294.1.91
  91. Glaser R, York AE. Testosterone therapy in women: Myths and misconceptions. Maturitas. 2019;124:94-98. doi:10.1016/j.maturitas.2019.03.016
  92. Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women’s Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2017;14(6):747-761. doi:10.1016/j.jsxm.2017.04.008
  93. Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi:10.1016/S2213-8587(19)30189-5
  94. Bolour S, Braunstein G. Testosterone therapy in women: a review. Int J Impot Res. 2005;17(5):399-408. doi:10.1038/sj.ijir.3901334
  95. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000;343(10):682-688. doi:10.1056/NEJM200009073431002
  96. Somboonporn W, Bell RJ, Davis SR. Testosterone use in women: how should we prescribe it? Maturitas. 2007;58(2):169-180. doi:10.1016/j.maturitas.2007.08.008
  97. Davis SR, Moreau M, Kroll R, et al. Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen. N Engl J Med. 2008;359(19):2005-2017. doi:10.1056/NEJMoa0707302
  98. Panay N, Al-Azzawi F, Bouchard C, et al. Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric. 2010;13(2):121-131. doi:10.3109/13697131003675911
  99. Basson R, Wierman ME, van Lankveld J, Brotto L. Summary of the recommendations on sexual dysfunctions in women. J Sex Med. 2010;7(1 Pt 2):314-326. doi:10.1111/j.1743-6109.2009.01617.x
  100. Elraiyah T, Sonbol MB, Wang Z, et al. Clinical Review: The Benefits and Harms of Systemic Testosterone Therapy in Postmenopausal Women With Normal Adrenal Function: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2014;99(10):3543-3550. doi:10.1210/jc.2014-2262
  101. Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab. 2005;90(9):5226-5233. doi:10.1210/jc.2004-1747
  102. Buster JE, Kingsberg SA, Aguirre OA, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005;105(5 Pt 1):944-952. doi:10.1097/01.AOG.0000158103.60707.93

Follow Newspatron on Google News

Google News Follow

Free. Get Newspatron stories in your Google News feed.